Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers

Breast Cancer Research and Treatment

Volumn 78, Issue 1, 2003, Pages 45-50

  Egawa, Chiyomi ^a   Motomura, Kazuyoshi ^b   Miyoshi, Yasuo ^a   Takamura, Yuuki ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Inaji, Hideo ^b   Koyama, Hiroki ^b   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

BRCA1; BRCA2; Breast cancer; Cyclophosphamide; Epirubicin

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR RECURRENCE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GENE EXPRESSION; GENES, BRCA1; GENES, BRCA2; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS;

EID: 0037368187     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022101310500     Document Type: Article

References (26)

1. Capranico G, Zunino F, Kohn KW, Pommier Y: Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29: 562-569, 1990
2. Camaggi CM, Strocchi E, Carisi P, Martoni A, Melotti B, Pannuti F: Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. Cancer Chemother Pharmacol 32: 301-309, 1993
3. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R: Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A: 1002-1007, 1994
4. Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Lee KB: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65-72, 1997
5. Faneyte IF, Kristel PM, van de Vijver MJ: Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: 114-122, 2001
6. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, Goldhirsch A: Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35: 574-579, 1999
7. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000
8. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001
9. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 37: 347-354, 2001
10. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Russell B, Rosenthal J, Hussey C, Tran T, McClure M, Frye C. Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Hetvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994
11. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH. Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene. BRCA2, to chromosome 13q12-13. Science 265: 2088-2090, 1994
12. Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, Andrulis IL, Lu J, Ho FC: Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 18: 4643-4646, 1999
13. Weber BH, Brohm M, Stec I, Backe J, Caffier H: A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 59: 962-964, 1996
14. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA: BRCA2 mutations in primary breast and ovarian cancers. Nature Genet 13: 238-240, 1996
15. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y: Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13: 245-247, 1996
16. Bieche I, Nogues C, Lidereau R: Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 18: 5232-5238, 1999
17. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI: BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84: 258-262, 1999
18. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res 92: 624-630, 2001
19. Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet 16: 69-74, 2000
20. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T: The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276: 14537-14540, 2001
21. Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110, 2001
22. Ormrod D, Holm K, Goa K, Spencer C: Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 15: 389-416, 1999
23. Fleming RA: An overview of cyctophosphamide and ifosfamide pharmacology. Pharmacotherapy 17(5 Pt 2): 146S-154S. 1997
24. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996
25. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33: 362-371, 1997
26. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T: Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85: 2200-2205, 1999